Ultragenyx Pharmaceutical Inc. Form SC 13G February 13, 2015 **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 **SCHEDULE 13G** (Amendment No. __)* **Under the Securities Exchange Act of 1934** Ultragenyx Pharmaceutical Inc. (Name of Issuer) Common Stock, par value \$0.001 per share (Titles of Class of Securities) 90400D108 (CUSIP Number) **December 31, 2014** (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

- o Rule 13d-1(c)
- x Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the *Notes*).

^{*} The remainder of this cover page shall be filled out of a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

```
CUSIP
             13G Page 2 of 9
90400D108
      NAME OF REPORTING
      PERSON
      I.R.S. IDENTIFICATION
      NO. OF ABOVE
      PERSON (ENTITIES
1
      ONLY)
      TPG Group Holdings
      (SBS) Advisors, Inc.
      CHECK THE
      APPROPRIATE BOX IF
      A MEMBER OF A
      GROUP
2
      (a) o
      (b) o
3
      SEC USE ONLY
      CITIZENSHIP OR
      PLACE OF
4
      ORGANIZATION
      Delaware
           SOLE VOTING
           POWER
NUMBER <sup>5</sup>
OF
           - 0 -
           SHARED
SHARES 6
           VOTING POWER
BENEFICIALLY596,420
           SOLE
OWNED
           DISPOSITIVE
BY
        7 POWER
EACH
           - 0 -
        8
           SHARED
REPORTING DISPOSITIVE
           POWER
PERSON
```

1,596,420

WITH:

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,596,420

10 CHECK BOX IF THE
AGGREGATE AMOUNT
IN ROW (9) EXCLUDES
CERTAIN SHARES o
PERCENT OF CLASS
REPRESENTED BY
11 AMOUNT IN ROW 9

4.6% (1) TYPE OF REPORTING PERSON

12

CO

(1) Based on a total of 34,846,472 shares of Common Stock (as defined below) of the Issuer (as defined below) outstanding as of February 5, 2015 as reported in the prospectus supplement filed by the Issuer with the Securities and Exchange Commission (the "Commission") on February 5, 2015.

```
CUSIP No.
             13GPage 3 of 9
90400D108
      NAME OF REPORTING
      PERSON
      I.R.S. IDENTIFICATION
1
      NO. OF ABOVE
      PERSON (ENTITIES
      ONLY)
      David Bonderman
      CHECK THE
      APPROPRIATE BOX IF
      A MEMBER OF A
      GROUP
2
      (a) o
      (b) o
3
      SEC USE ONLY
      CITIZENSHIP OR
      PLACE OF
      ORGANIZATION
4
      United States
           SOLE VOTING
           POWER
NUMBER<sup>5</sup>
OF
           - 0 -
           SHARED
SHARES 6
           VOTING POWER
BENEFICIALLY596,420
           SOLE
OWNED
           DISPOSITIVE
BY
        7
           POWER
EACH
           - 0 -
           SHARED
REPORTING
           DISPOSITIVE
PERSON<sup>8</sup>
           POWER
           1,596,420
WITH:
9
      AGGREGATE AMOUNT
```

BENEFICIALLY

OWNED BY EACH REPORTING PERSON

1,596,420

10 CHECK BOX IF THE
AGGREGATE AMOUNT
IN ROW (9) EXCLUDES
CERTAIN SHARES o
PERCENT OF CLASS
REPRESENTED BY
11 AMOUNT IN ROW 9

4.6% (2) TYPE OF REPORTING PERSON

12

IN

(2) Based on a total of 34,846,472 shares of Common Stock of the Issuer outstanding as of February 5, 2015 as reported in the prospectus supplement filed by the Issuer with the Commission on February 5, 2015.

CUSIP No. 90400D108 13G Page 4 of 9

NAME OF REPORTING PERSON

I.R.S. IDENTIFICATION

NO. OF ABOVE
PERSON (ENTITIES
ONLY)

James G. Coulter CHECK THE

2

APPROPRIATE BOX IF

```
A MEMBER OF A GROUP
```

- (a) o
- (b) o
- 3 SEC USE ONLY CITIZENSHIP OR PLACE OF
- 4 ORGANIZATION

United States

SOLE VOTING

POWER

NUMBER ⁵

OF - 0 -

SHARED

SHARES 6 VOTING POWER

BENEFICIALLY596,420

SOLE

OWNED DISPOSITIVE

BY 7 POWER

EACH - 0 -

REPORTING SHARED

DISPOSITIVE

PERSON⁸

WITH: 1,596,420

AGGREGATE AMOUNT

BENEFICIALLY OWNED BY EACH REPORTING PERSON

POWER

1,596,420

AGGREGATE AMOUNT
IN ROW (9) EXCLUDES
CERTAIN SHARES o
PERCENT OF CLASS

REPRESENTED BY

CHECK BOX IF THE

11 AMOUNT IN ROW 9

4.6% (3)

12

9

TYPE OF REPORTING PERSON

IN

(3) Based on a total of 34,846,472 shares of Common Stock of the Issuer outstanding as of February 5, 2015 as reported in the prospectus supplement filed by the Issuer with the Commission on February 5, 2015.

Item 1(a). Name of Issuer:
Ultragenyx Pharmaceutical Inc. (the <u>"Issuer"</u>)
Item 1(b). Address of Issuer's Principal Executive Offices:
60 Leveroni Court
Novato, California 94949
Item 2(a). Name of Person Filing:
This Schedule 13G is being filed jointly by TPG Group Holdings (SBS) Advisors, Inc., a Delaware corporation ("Group Advisors"), David Bonderman and James G. Coulter (each, a "Reporting Person" and, together, the "Reporting Persons"), pursuant to an Agreement of Joint Filing incorporated by reference herein in accordance with Rule 13d-1(k)(1) under the Act.
Group Advisors is the general partner of TPG Group Holdings (SBS), L.P., a Delaware limited partnership, which is the sole member of TPG Holdings I-A, LLC, a Delaware limited liability company, which is the general partner of TPG Holdings I, L.P., a Delaware limited partnership, which is the sole member of TPG Biotechnology GenPar III Advisors, LLC, a Delaware limited liability company, which is the general partner of TPG Biotechnology GenPar III, L.P., a Delaware limited partnership, which is the general partner of TPG Biotechnology Partners III, L.P., a Delaware limited partnership (<u>"TPG Biotech II</u> I"), which directly holds 1,596,420 shares of Common Stock of the Issuer (the <u>"Shares"</u>) reported herein. Because of Group Advisors' relationship to TPG Biotech III, Group Advisors may be deemed

David Bonderman and James G. Coulter are officers and sole shareholders of Group Advisors, and may therefore be deemed to beneficially own the Shares held by TPG Biotech III. Messrs. Bonderman and Coulter disclaim beneficial ownership of the Shares except to the extent of their pecuniary interest therein.

Item 2(b). Address of Principal Business Office or, if none, Residence:

to beneficially own the Shares directly held by TPG Biotech III.

The principal business address of each of the Reporting Persons is as follows:
c/o TPG Global, LLC
301 Commerce Street, Suite 3300
Fort Worth, Texas 76102
Item 2(c). Citizenship:
See response to Item 4 of each of the cover pages.
Item 2(d). Titles of Classes of Securities:
Common Stock, par value \$0.001 per share.
Item 2(e). CUSIP Number:
90400D108
Page 5 of 9

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a(n):

- (a) Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 780).
- (b) Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
- (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
- (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e) "Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
- (f) "Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
- (g) Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
- (h) "Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (13 U.S.C. 1813).
- (i) ".Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
- (j) "Non-U.S. institution, in accordance with § 240.13d-1(b)(1)(ii)(J).
- (k) "Group in accordance with §240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J), please specify the type of institution:

Page 6 of 9

Item 4. Ownership	
(a)	Amount beneficially owned:
See responses to Item 9 on each cover page	·.
(b)	Percent of class:
See responses to Item 11 on each cover pag	re.
(c)	Number of shares as to which such person has:
(i)	Sole power to vote or to direct the vote:
See responses to Item 5 on each cover page	s.
(ii)	Shared power to vote or to direct the vote:
See responses to Item 6 on each cover page	·.
(iii) S	Sole power to dispose or to direct the disposition of:
See responses to Item 7 on each cover page	».
(iv) Sha	ared power to dispose or to direct the disposition of:
See responses to Item 8 on each cover page	s.

Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not Applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
the Parent Holding Company.
See response to Item 2(a) above.
Item 8. Identification and Classification of Members of the Group.
item 6. Identification and Classification of Members of the Group.
Not Applicable
Not Applicable.
Item 9. Notice of Dissolution of Group.
Net Applicable
Not Applicable.
Item 10. Certification.
Not Applicable.
Page 7 of 9

SIGNATURE

After reasonable inquiry and to the best of	of my knowledge and	belief, I certify that	the information set	forth in this
statement is true, complete and correct.				

Dated: February 13, 2015

TPG Group Holdings (SBS) Advisors, Inc.

By: <u>/s/ Ronald Cami</u> Name: Ronald Cami Title: Vice President

David Bonderman

By: /s/ Ronald Cami

Name: Ronald Cami, on behalf of David Bonderman (4)

James G. Coulter

By: /s/ Ronald Cami

Name: Ronald Cami, on behalf of James G. Coulter (5)

14

- (4) Ronald Cami is signing on behalf of Mr. Bonderman pursuant to an authorization and designation letter dated July 1, 2013, which was previously filed with the Commission as an exhibit to a Schedule 13D filed by Mr. Bonderman on August 14, 2013 (SEC File No. 005-83906).
- (5) Ronald Cami is signing on behalf of Mr. Coulter pursuant to an authorization and designation letter dated July 1, 2013, which was previously filed with the Commission as an exhibit to a Schedule 13D filed by Mr. Coulter on August 14, 2013 (SEC File No. 005-83906).

Page 8 of 9

Exhibit Index

Exhibit 1 Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.*

* Incorporated herein by reference to the Agreement of Joint Filing by TPG Advisors II, Inc., TPG Advisors III, Inc., TPG Advisors V, Inc., TPG Advisors VI, Inc., T3 Advisors, Inc., T3 Advisors II, Inc., TPG Group Holdings (SBS) Advisors, Inc., David Bonderman and James G. Coulter, dated as of February 14, 2011, which was previously filed with the Commission as Exhibit 1 to Schedule 13G filed by TPG Group Holdings (SBS) Advisors, Inc., David Bonderman and James G. Coulter on February 14, 2011.

Page 9 of 9